title: Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV).
abstract: Respiratory Syncytial Virus infections are one of the leading causes of severe respiratory diseases that require hospitalization and, in some cases, intensive care. Once resolved, there may be respiratory sequelae of varying severity. The lack of effective treatments for bronchiolitis and the lack of vaccines for RSV accentuate the role of prevention in decreasing the impact of this disease. Prevention of bronchiolitis strongly relies on the adoption of environment and the hygienic behavior measures; an additional prophylactic effect may be offered, in selected cases, by Palivizumab, a humanized monoclonal antibody produced by recombinant DNA technology, able to prevent RSV infection by blocking viral replication.After many years the Italian Society of Neonatology, on the basis of the most recent scientific knowledge, has decided to revise recommendations for the use of palivizumab in the prevention of RSV infection.
authors.affiliation: Unità di Neonatologia, Patologia Neonatale e Terapia Intensiva, Policlinico S. Matteo, Pavia, Italy. L.Bollani@smatteo.pv.it.
authors.forename: Lina
authors.initials: L
authors.lastname: Bollani
authors.affiliation: U.O.C. Terapia Intensiva e patologia neonatale, A.O. Padova, Padova, Italy. baraldi@pediatria.unipd.it.
authors.forename: Eugenio
authors.initials: E
authors.lastname: Baraldi
authors.affiliation: U.O. C. Neonatologia e Terapia Intensiva neonatale, A.O. Spedali civili, Brescia, Italy. gaechir@tin.it.
authors.forename: Gaetano
authors.initials: G
authors.lastname: Chirico
authors.affiliation: U.O.C. Terapia intensiva neonatale, Ospedale pediatrico Bambino Gesù, Roma, Italy. andrea.dotta@opbg.net.
authors.forename: Andrea
authors.initials: A
authors.lastname: Dotta
authors.affiliation: U.O. Pediatria E Neonatologia , Ospedale Nuovo S. Maria della Scaletta, Imola, Italy. m.lanari@ausl.imola.bo.it.
authors.forename: Marcello
authors.initials: M
authors.lastname: Lanari
authors.affiliation: U.O. Utin e Neonatologia, Azienda Ospedaliera di Venere e Giovanni XXIII, Bari, Italy. delveccant@libero.it.
authors.forename: Antonello
authors.initials: A
authors.lastname: Del Vecchio
authors.affiliation: U.O. Neonatologia e TIN ospedaliera, Azienda Ospedaliera OIRM-S. Anna, Torino, Italy. paolomanzoni@hotmail.com.
authors.forename: Paolo
authors.initials: P
authors.lastname: Manzoni
authors.affiliation: U.O. Nido, Patologia Neonatale e Terapia Intensiva Neonatale, Ospedale Santa Chiara, Pisa, Italy. antonio.boldrini@med.unipi.it.
authors.forename: Antonio
authors.initials: A
authors.lastname: Boldrini
authors.affiliation: U.O. Divisione di Neonatologia, Policlinico Caslino, Roma, Italy. piermpa@tin.it.
authors.forename: Piermichele
authors.initials: P
authors.lastname: Paolillo
authors.affiliation: U.O. Neonatologia, Presidio Ospedaliero S. Salvatore, L'Aquila, Italy. sandra.difabio@virgilio.it.
authors.forename: Sandra
authors.initials: S
authors.lastname: Di Fabio
authors.affiliation: U.O. Nido, Patologia Neonatale e Terapia Intensiva Neonatale, Azienda Ospedaliera G. Rummo, Benevento, Italy. luigi.orfeo@ao-rummo.it.
authors.forename: Luigi
authors.initials: L
authors.lastname: Orfeo
authors.affiliation: Unità di Neonatologia, Patologia Neonatale e Terapia Intensiva, Ospedale Policlinico S. Matteo, Pavia, Italy. m.stronati@smatteo.unipv.it.
authors.forename: Mauro
authors.initials: M
authors.lastname: Stronati
authors.affiliation: U.O.C. Neonatologia, Policlinico Universitario A. Gemelli, Roma, Italy. cromagnoli@rm.unicatt.it.|Division of Neonatology, Department of Pediatrics, Catholic University S.H., Largo A. Gemelli,8, Rome, 00168, Italy. cromagnoli@rm.unicatt.it.
authors.forename: Costantino
authors.initials: C
authors.lastname: Romagnoli
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use; D004279:DNA, Viral / Q000032:analysis; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000517:prevention & control* / Q000821:virology; D000069455:Palivizumab / Q000627:therapeutic use*; D018357:Respiratory Syncytial Virus Infections / Q000517:prevention & control* / Q000821:virology; D012136:Respiratory Syncytial Viruses / Q000302:isolation & purification*
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D000069455:Palivizumab